tlr7 agonist jnj-64794964
Generic: TLR7 Agonist JNJ-64794964
tlr7 agonist jnj-64794964: 1 clinical trial tracked.
tlr7 agonist jnj-64794964 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about tlr7 agonist jnj-64794964, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Evaluate TQ-A3334 Tablets Combined Nucleoside (Acid) Analogs in the Initial Treatment/Chronic Hepatitis B Virus (HBV) Infection Subjects of Chronic HBV Infection
Primary endpoint: At 24 weeks, the changes in serum HBSAG relative to the baseline
InterventionalRandomizedquadruple116 targetStarted 2024-12Completion 2026-0615 sites · ChinaChia Tai Tianqing Pharmaceutical Group Co., Ltd.